Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.

Date publication

juillet 2012

Journal

AIDS (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HERBEIN Georges , Pr ROHR Olivier

Tous les auteurs :
Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22555163

Résumé

Reactivation of HIV-1 expression in persistent reservoirs together with an efficient HAART has been proposed as an adjuvant therapy aimed at reaching a functional cure for HIV. Previously, H3K9 methylation was shown to play a major role in chromatin-mediated repression of the HIV-1 promoter. Here, we evaluated the therapeutic potential of histone methyltransferase inhibitors (HMTIs) in reactivating HIV-1 from latency.

Mots clés

Antiretroviral Therapy, Highly Active, Azepines, pharmacology, CD4-Positive T-Lymphocytes, immunology, Disease Reservoirs, HIV Infections, drug therapy, HIV-1, immunology, Histocompatibility Antigens, Histone-Lysine N-Methyltransferase, antagonists & inhibitors, Humans, Leukocytes, Mononuclear, immunology, Methyltransferases, antagonists & inhibitors, Piperazines, pharmacology, Quinazolines, pharmacology, Repressor Proteins, antagonists & inhibitors, Virus Latency, drug effects

Référence

AIDS. 2012 Jul;26(12):1473-82